Potential roles of mitochondrial cofactors in the adjuvant mitigation of proinflammatory acute infections, as in the case of sepsis and COVID-19 pneumonia

Many researchers have postulated that systemic inflammation, accompanied by elevated levels of TNF-α, IL-1 and PDGF, was the main determinant of the pathogenesis of sepsis and septic shock [41]. The relationship between increased production of nitric oxide, antioxidant depletion and a decrease in the activity of complex I of the respiratory chain in patients with sepsis has been well demonstrated [42, 43]. Persistent inflammation during sepsis can be caused by overproduction of mitochondrial ROS (mtROS) with consequent mitochondrial damage and MDF. Since the main role of mitochondria is to supply cells with energy, the above consequences should lead to a decrease in the synthesis of ATP. Indeed, decreased levels of ATP in the liver [44], kidney [45] and blood [46] were associated with the severity of sepsis [46, 47]. Although data on ATP levels and mitochondrial function are still emerging in COVID-19 patients, there are many reasons for drawing parallels with sepsis. In particular, the most recent work by Gibellini et al. [48] shows a decrease in ATP and MDF levels in patients infected with SARS-CoV-2. This means that mitochondria may be dysfunctional and unable to cope with the hypermetabolic demands associated with COVID-19 sepsis. Excessive ROS levels have also been seen in critically ill patients with COVID-19, indicating MDF’s involvement in the disease [49, 50]. In general, approaches targeting mtROS should be incorporated into preventive and therapeutic strategies against sepsis [7] and COVID-19-associated sepsis [51]. One such approach may be metabolic resuscitation with MNs, which can prevent uncontrolled production of mtROS and help maintain tissue homeostasis during these diseases.

Over the past several decades, a body of literature has established distinct, yet complementary, roles of MNs in mitochondrial functions [52, 53]. Comprehensive recent reviews have been focused on the roles and on the prospective potential clinical utilization application of α-lipoic acid (ALA) [54‐56], coenzyme Q10 (CoQ10) [8, 57‐60] and carnitine (CARN) [61, 62]. We have reported previously on the combined features of MDF, prooxidant state and prospective use of MNs in an extensive number of chronic, age-related or genetic disorders [6, 63‐67]. Unlike chronic disorders, a relatively lesser body of literature has been focused on acute disorders, in spite of their—quite obvious—association with a prooxidant state as in, for example, sepsis.

The relative roles of each MN in counteracting acute prooxidant conditions are reported in the following tables, with data deriving from in vitro and animal studies and from clinical trials.

As shown in Table 1, in vitro studies have shown the relevance of each MN in a number of prooxidant-related conditions. Murine, rat and human cell lines, characterized by prooxidant state endpoints, were tested for antioxidant effects of ALA, which was found to inhibit signal-regulated kinase-1 (ERK1), prooxidant interleukins and other OS biomarkers [68‐73]. An analogous antioxidant action was found by Schmelzer et al. [74] by testing CoQ10 in murine cells, which exerted anti-inflammatory properties via NFκB1-dependent gene expression. Further studies on models of inflammation included human endothelial cells at different levels of replicative senescence which were challenged with LPS. In this context, the reduced form of CoQ10 was particularly effective in preventing the modulation of inflammatory markers that characterize the senescence-associated inflammatory phenotype [75]. Further, CARN, when tested in rat renal cells or cardiomyocytes, was found to enhance SOD2 expression and to counteract OS and inflammation [76, 77]. Taken together, these studies of the in vitro MN-associated antioxidant effects provide a body of evidence suggesting a protective antioxidant action of MNs at the organismal level.

Testing of the effects of MNs in animal models of acute inflammation conditions is summarized in Table 2. A number of studies in the recent decade have tested the ALA-associated anti-inflammatory effects on rats [78‐86] and mice [87, 88]. The model disorders included multiple-organ sepsis [78, 81, 82, 86], endotoxemia [79], metal or organic poisoning [81, 84], and radiation-induced damage [88]. Altogether, ALA administration was found to decrease inflammatory response, H₂O₂, MDA levels, myeloperoxidase activity, and cytokine levels. Thus, the body of evidence for ALA-associated anti-inflammatory actions provides strong suggestions toward the adjuvant use of this MN in counteracting inflammatory conditions.

CoQ10 was also tested in rat and mouse models (Table 2), for its ability to counteract inflammatory conditions as drug-induced [89], or in puncture-induced sepsis [90], or experimental cerebral malaria [91].

Overall, CoQ10 was found to decrease MDA, TBARS and 8-OH-dG. Though through a more limited body of evidence compared to ALA, also CoQ10-associated anti-inflammatory properties may suggest the grounds for the design of adjuvant clinical treatments in acute disorders.

The animal studies of CARN- or acetyl-CARN-induced protection against proinflammatory conditions were focused on the same set of test-induced noxae (steatohepatitis, peritonitis, neuroinflammation) [92‐95], as shown in Table 2. The results showed that (acetyl-)CARN decreased the levels of several proinflammatory endpoints, including proinflammatory markers, NF-ĸB and IL-1 and IL-6, and ameliorated organ inflammation [96, 97].

Thus, from the evidence provided in animal studies, each MN provides multiple means of protection against a number of proinflammatory conditions.

The reports from clinical trials on MNs in acute disorders are relatively few compared to the wealth of literature assessing the positive effects of MNs in several chronic diseases, such as type 2 diabetes and aging-related or cardiovascular disorders. An example of this growing body of literature on clinical trials in a number of chronic disorders may be found in our review [6], which cites a total of 262 reports on clinical trials testing MN-associated protective effects in patients affected by an extensive number of chronic disorders. As shown in Table 3, ALA was administered to patients admitted for hemodialysis [98], or undergoing cardiopulmonary surgery [99], or affected by ischemia—reperfusion injury [100]. Following ALA administration, patients underwent decrease in inflammatory markers, C-reactive protein (CRP), and IL-6 and IL-8 levels.

CoQ10 levels were significantly lower in patients with acute influenza infection [101, 102]. CoQ10-supplemented patients showed decreased levels of inflammatory markers such as IL‐2 and TNF‐α, although no correlation with IL‐6 and IL‐10 was found [102]. Patients affected by papillomavirus skin warts and administered with CoQ10 underwent decreased viral load and increased antiviral cytokine levels [103] (Table 3).

CoQ10 was shown to improve clinical parameters as well as MDF in septic patients who received 100 mg CoQ10 twice a day for 7 days. In a randomized trial (n = 40), decreased levels of TNF-α and malondialdehyde were obtained in the early phase of septic shock patients [104].

Concurrent reports on CARN administration to patients undergoing hemodialysis [105‐107], or septic shock [108] or affected by coronary artery disease [109], or perioperative atrial fibrillation [110] found CARN-induced significant decrease in CRP or decreased mortality, as shown in Table 3. The relevance of CRP in inflammation and OS had been established in early studies [111], thus the adjuvant role of CARN in mitigating a number of proinflammatory conditions should be ascertained.

Based on the evidence from experimental studies and from clinical trials, it may be concluded that separate administration of ALA, coQ10, or CARN is safe in human and in animal health. Thus, as conceptually depicted in Fig. 1, both ALA and CARN were found to lower the levels of several inflammation biomarkers, such as CRP, both in animal models [71] and in humans [100, 101, 104, 105]. Another direct link of proinflammatory conditions with MNs was provided by Donnino et al. [101] and by Chase et al. [102], who reported decreased CoQ10 plasma levels in patients affected by septic shock or by acute influenza.

A question may be raised about using individual MN administration in acute disorders, without any known attempt to test two or three combined MNs. Only a few clinical trials [122, 126, 127] investigated the effects of two combined MNs in chronic disorders, while no report is available—to the best of our knowledge—in testing three MNs concurrently.

Although there are no reports of the combined use of the three MNs in humans, any combined administration should not present potential problems when administered in patients suffering from acute disorders. According to the major and distinct interactions of MNs displayed in inflammatory conditions, as summarized in Fig. 1, it may be expected that: (a) CoQ10 administration should counteract the reported CoQ10 deficiency associated with inflammation and (b) both ALA and CARN administration should contribute to decreasing a set of inflammation biomarkers including, but not confined to, CRP. The present state-of-art is confined to clinical trials in one MN. This might be seen as a self-mutilation in the frame of adjuvant strategies targeted to mitigation of inflammatory conditions, such as sepsis, influenza, pneumonia, or other acute disorders. Taken together, the available knowledge about safety and anti-inflammatory effectiveness of each MN should prompt the combined use of these autochthonous cofactors in adjuvant therapeutic design originally designed for mitochondrial diseases [128]. The same rationale may be designed in view of mitigating acute disorders such as pneumonia infections. So far, clinical management of COVID-19 has been suggested by means of blocking cytokine storm through corticosteroids [129] or cytokine inhibitors [130, 131], controlling systemic inflammation via intravenous immunoglobulins injection [132], or inhibition of Janus kinases [133], and intervention with antimalarial drugs to inhibit tissue infection and viral replication [134]. It is worth noting that tocilizumab, as tested in COVID-19 [132, 133], is a well-established IL-6-blocking drug used in rheumatoid arthritis, both decreasing OS and MDF [135, 136].

Counteracting the course of disorders characterized by a prooxidant state has been a goal of an extensive body of experimental and clinical literature (as summarized in Tables 2, 3). Apart from the attempts to utilize MNs for this purpose, a long list of natural or synthetic antioxidants, vitamins and herbal preparations has been reported in the literature focused on mitigating COVID-19 progression [31‐38]. Without regarding MNs as alternative means in counteracting inflammation, one might suggest combining these agents with well-established antioxidants, such as melatonin and/or resveratrol [31, 35].

However, with regard to MNs and the broader field, a major question arises about the quantification of the redox properties of any unspecified “antioxidant”, such as redox potential. To date, attempts to accomplish this task are frustrated by the multiplicity of parameters to be considered to obtain an endpoint that may be considered valid for this purpose. These parameters, mostly obtained in physico-chemical studies, encompass a number of variables, such as temperature, pH, concentration, dimerization, and multiple free radical formation [137‐139]; thus, an effort to compare the antioxidant actions of several chemicals is presently unavailable. This therefore may suggest the timeliness of a quantitative comparison of antioxidant actions, under defined—physiological—conditions such as ionic strength, pH, and temperature, which may reflect the parameters detected in basal vs. pathological conditions. To provide an experimental and clinical choice among the multitude of antioxidants, this investigation, as yet unaccomplished, is much warranted.